GeneTether: Roland Boivin, Jean Jen, and Peter Sampson
Biotech company GeneTether, which develops technologies to increase the correction efficiency of targeted genome editing technologies, has appointed Roland Boivin as CEO, Jean Jen as CFO, and Peter Sampson as vice president of R&D.
Boivin has nearly 25 years of public company leadership experience, with a focus on strategic operations, finance, business development, and general management. He most recently served as CFO of Medexus Pharmaceuticals. Prior to joining Medexus, Boivin served as CFO of Golden Hope Mines, and held a variety of progressive positions at 3M Canada, including leading the company's consumer division as business unit manager, and serving as a member of the firm's executive committee.
Boivin succeeds Har Grover, who will continue to serve in a consulting role at GeneTether until the end of 2021.
Jen has more than 12 years of finance and accounting experience in the life sciences sector, having worked with businesses ranging from venture-backed start-ups to publicly traded companies. She has held various senior level positions as an independent financial consultant, and most recently served as VP of finance at Anandia Laboratories. From 2013 to 2018, Jen held increasingly senior positions at Arbutus Biopharma, and previously spent nearly five years with KPMG's advisory and audit practices, with a primary focus on publicly-listed companies.
Sampson has more than 20 years of drug development experience, including discovery chemistry, CMC regulatory affairs, and IP portfolio management. He joins GeneTether from Scientus Pharma where he served as the director of R&D. Prior to Scientus, Sampson spent 10 years as a scientist in the therapeutics group at the University Health Network. Prior to UHN, he held various R&D leadership roles of increasing responsibility at Affinium Pharmaceuticals, GlycoDesign, and Albany Molecular Research.